Affimed N.V. (AFMD) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. There were no new wire items for AFMD in the last 30 days. The most recent was published May 20, 2025.
Latest news
25 items- SECAmendment: SEC Form SCHEDULE 13G/A filed by Affimed N.V.SCHEDULE 13G/A - Affimed N.V. (0001608390) (Subject)
- ANALYSTAffimed Therapeutics downgraded by H.C. WainwrightH.C. Wainwright downgraded Affimed Therapeutics from Buy to Neutral
- SECSEC Form 6-K filed by Affimed N.V.6-K - Affimed N.V. (0001608390) (Filer)
- PRAffimed Announces Receipt of Nasdaq Delisting NoticeMANNHEIM, Germany, May 14, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it has received a written notice from the staff of the Nasdaq Listing Qualifications Department (the "Staff") notifying the Company that, in accordance with Nasdaq Listing Rule 5101, 5110(b) and IM-5101-1, the trading of the Company's common shares will be suspended at the opening of business on May 20, 2025, and a Form 25 Notification of Delisting will be filed with the U.S. Securities Exchange Commission to delist the Company's securities from The Nasdaq Stock Market ("Nasdaq")
- ANALYSTAffimed Therapeutics downgraded by Leerink PartnersLeerink Partners downgraded Affimed Therapeutics from Outperform to Market Perform
- SECSEC Form 6-K filed by Affimed N.V.6-K - Affimed N.V. (0001608390) (Filer)
- PRAffimed Announces Filing for the Opening of Insolvency ProceedingsMANNHEIM, Germany, May 13, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced its decision to file an application for opening of insolvency proceedings with the local court of Mannheim in Germany. As previously reported, Affimed N.V. (the "Company") has been engaged in discussions with potential investors and partners with respect to potential strategic transactions to raise additional capital. Despite its continuous and ongoing fundraising efforts, the Company has not been able to raise sufficient additional funds to continue the operations of the Company and
- SECSEC Form NT 20-F filed by Affimed N.V.NT 20-F - Affimed N.V. (0001608390) (Filer)
- PRAffimed Shows Higher Exposure of AFM24 is Associated with Significantly Higher Response Rates and Progression-Free Survival in Refractory NSCLC Patients at AACR Annual MeetingAn exposure-outcome analysis in 72 patients with refractory non-small cell lung cancer (NSCLC) who received AFM24 at 480 mg weekly demonstrates that higher drug exposure (above median) leads to improved objective response rate (33.3% vs 5.6%) and longer progression free survival (PFS) (7.3 mo. vs 2.9 mo.) without a negative impact on safetyThese findings will be incorporated in future AFM24 trials to further improve efficacy outcomes of patients treated with AFM24 MANNHEIM, Germany, April 29, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today presented findings on an ex
- PRAffimed Announces Acceptance of Three Abstracts for Presentation at the American Society for Clinical Oncology Annual MeetingMANNHEIM, Germany, April 23, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD) ("Affimed", or the "Company"), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced an abstract on the phase 2 LuminICE-203 study of its innate cell engager (ICE®) acimtamig in combination with AlloNK® (AB-101) has been accepted for an oral presentation at the Annual Meeting of the American Society for Clinical Oncology (ASCO) taking place May 30 – June 3, 2025 in Chicago, Illinois. In addition, two abstracts on AFM24 in combination with atezolizumab in non-small cell lung cancer (NSCLC) have been accepted as poster presentations. Det
- SECSEC Form 6-K filed by Affimed N.V.6-K - Affimed N.V. (0001608390) (Filer)
- PRAffimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price RequirementMANNHEIM, Germany, April 21, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it has received a written notice (the "Notice"), dated April 15, 2025, from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") indicating that, for the last thirty (30) consecutive business days, the bid price for the Company's common shares had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq under Nasdaq Listing Rule 5450(a)(1) (the "Minimum Bid Price Rule"). In accordance with Nasdaq Listing Rule 5810(c)(3
- PRAffimed Announces Acceptance of AFM24 Abstract on Dose Optimization for Presentation at American Association for Cancer Research Annual MeetingMANNHEIM, Germany, March 25, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced an abstract on AFM24 dose optimization using exposure response analysis has been accepted for presentation as a poster at the Annual Meeting of the American Association for Cancer Research (AACR) taking place April 25-30, 2025 in Chicago, Illinois. Details of the poster presentation are as follows: Title: Dose-Optimization Using Exposure Response Analysis in AFM24 (in Monotherapy and with Atezolizumab) in Patients with Advanced/Metastatic Non-Small Cell Lung Cancer Authors: Antho
- PRAffimed to Present at the Leerink Partners Global Healthcare Conference 2025MANNHEIM, Germany, March 03, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD) ("Affimed", or the "Company"), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that its Chief Executive Officer, Dr. Shawn Leland, PharmD, RPh, will participate in a fireside chat at the Leerink Partners Global Healthcare Conference 2025 on Tuesday, March 11, 2025 at 2:20 p.m. Eastern Daylight Time. A live webcast of the presentation will be accessible on Affimed's website at https://www.affimed.com/investors/webcasts-and-corporate-presentation/. A replay of the call will be archived on Affimed's website for 30 days after the c
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Affimed N.V.SCHEDULE 13G/A - Affimed N.V. (0001608390) (Subject)
- SECSEC Form 6-K filed by Affimed N.V.6-K - Affimed N.V. (0001608390) (Filer)
- PRAffimed Reports Positive Clinical Update on AFM24/Atezolizumab Combination Therapy in Non-Small Cell Lung Cancer (NSCLC)In 33 heavily pretreated NSCLC EGFR wild-type (EGFRwt) patients the combination of AFM24 and atezolizumab shows an overall response rate (ORR) of 21% (6 confirmed responses, 1 response awaiting confirmatory scan) and a disease control rate (DCR) of 76%; tumor shrinkage was observed in 48% of patients; preliminary median progression free survival (PFS) is 5.6 months and 36% of patients remain on treatmentIn 17 heavily pretreated NSCLC EGFR mutant (EGFRmut) patients the combination shows an ORR of 24% and a DCR of 71%; tumor shrinkage was observed in 41% of patients; median PFS is 5.6 months and 5 patients (29%) are on treatment for over 10 monthsBoth cohorts demonstrated a well-manageable sid
- PRAffimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)AFM28, a bispecific, tetravalent innate cell engager (ICE®) targeting CD123 and CD16A, achieved a 40% composite complete remission rate (CRcR) at the highest dose level (300 mg) in heavily pretreated R/R AML patientsAFM28 demonstrates a favorable safety profile: Grade 1 and 2 Infusion related reactions (IRRs) were the main related side effect, occurring in 45% of patients; no signs of neurotoxicity or immune-related side effects were observedBased on the good safety profile and likely dose-effect relationship, the evaluation of higher dose levels is planned MANNHEIM, Germany, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD) ("Affimed", or the "Company"), a clinical-stage immun
- PRAffimed to Host Investor Conference Call Highlighting Clinical Data from AFM24 in Combination with Atezolizumab in Non-Small Cell Lung CancerMANNHEIM, Germany, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD) ("Affimed", or the "Company"), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will host a conference call on Tuesday, December 17, at 8:30 a.m. EST / 14:30 CET to review clinical data from AFM24-102, the combination trial of its AFM24 innate cell engager ICE® with atezolizumab in non-small cell lung cancer. The conference call will be available via phone and webcast. The live audio webcast of the call will be available in the "Webcasts" section on the "Investors" page of the Affimed website at https://www.affimed.com/in
- PRAffimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK® Combination in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) PatientsThe combination of acimtamig with AlloNK® demonstrated an overall response rate of 86% and complete response of 55% in 22 heavily pretreated patients with R/R cHL, who have exhausted all standard of care treatmentsThe combination showed a well-manageable safety profile with no unexpected safety signals MANNHEIM, Germany, Dec. 08, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD) ("Affimed", or the "Company"), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced the presentation of data in a poster session at the 66th ASH Annual Meeting and Exposition. The dataset includes 22 patients from the run-in phase of the
- SECSEC Form 6-K filed by Affimed N.V.6-K - Affimed N.V. (0001608390) (Filer)
- PRAffimed Reports Third Quarter 2024 Financial Results & Business UpdateAFM24 combination with atezolizumab: The non-small cell lung cancer (NSCLC) EGFR wild-type (EGFRwt) cohort completed enrollment: Objective response rate (ORR) and safety data to be presented on a Company conference call on December 17, 2024.Acimtamig (AFM13) combination with AlloNK® (AB-101): Updated clinical data from the four cohorts of the run-in phase to be presented in a poster session at ASH 2024.AFM28 monotherapy phase 1 dose-escalation study: Updated clinical data to be presented at an oral presentation at ASH 2024.Cash runway into Q4 2025: As of September 30, 2024, cash, cash equivalents and investments were €24.1 million. Based on operating and financial plans cash-runway projected
- SECSEC Form EFFECT filed by Affimed N.V.EFFECT - Affimed N.V. (0001608390) (Filer)
- SECSEC Form 424B5 filed by Affimed N.V.424B5 - Affimed N.V. (0001608390) (Filer)
- PRAffimed to Report Third Quarter 2024 Financial Results & Corporate Update on November 14, 2024MANNHEIM, Germany, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release third quarter 2024 results and corporate update on Thursday, November 14, 2024. The Company will host a conference call at 8:30 a.m. EST / 14:30 CET. The conference call will be available via phone and webcast. The live audio webcast of the call will be available in the "Webcasts" section on the "Investors" page of the Affimed website at https://www.affimed.com/investors/webcasts-and-corporate-presentation/. To access the call by phone, please use link https://r
AFMD FAQ
8 questionsWhat does Affimed N.V. do?
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, which has completed Phase II clinical study of CD30-positive T-cell lymphoma, and hodgkin lymphoma (HL), as well as is in Phase II clinical trials for peripheral T-cell lymphoma, and transformed mycosis fungoides; that is in Phase I clinical study in combination with adoptive NK cells for CD30-postive lymphomas; and has completed Phase Ib clinical study in combination with anti-PD-1 antibody...What is the latest news on AFMD?
Quantisnow has not tracked any new filings, ratings or press releases for AFMD in the last 30 days. The most recent wire item was published on May 20, 2025.Where does AFMD stock trade?
Affimed N.V. (AFMD) is listed on NASDAQ.What sector and industry is AFMD in?
Affimed N.V. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Affimed N.V. go public?
Affimed N.V. (AFMD) completed its IPO in 2014.What are analysts saying about AFMD?
Across the last 8 analyst actions on Affimed N.V., there were 0 upgrades and 3 downgrades. The most recent action was from H.C. Wainwright: Neutral on 2025-05-14.What companies are similar to AFMD?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare AFMD side-by-side with any of them on Quantisnow.How can I track AFMD on Quantisnow?
Quantisnow aggregates Affimed N.V.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AFMD to receive live email and push alerts on every new disclosure.